drugset
drugset / Trial / NCT01702298

A Study to Assess the Safety and Tolerability of Sitagliptin/Simvastatin Fixed-dose Combination (FDC) in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-312)

NCT01702298 ↗

Phase 3 Completed 42 enrolled Merck Sharp & Dohme LLC
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to examine the safety and tolerability of sitagliptin 100 mg/simvastatin 40 mg FDC (MK-0431D) in Vietnamese participants with type 2 diabetes mellitus with inadequate glycemic control on metformin.

Timeline

Start
2012-12-07
Primary completion
2013-05-29
Completion
2013-05-29

Drugs

EvaluationDrugModalityDoseRoute
Subject Simvastatin Small molecule 40 mg Oral
Subject Sitagliptin Small molecule 100 mg Oral
Background Metformin Small molecule 1000 mg Oral

Indications

type 2 diabetes mellitus